...
首页> 外文期刊>Bone >The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases.
【24h】

The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases.

机译:使用护理点设备监测患有骨转移的癌症患者的骨吸收生物标志物尿N-端肽。

获取原文
获取原文并翻译 | 示例
           

摘要

Type I collagen is the major constituent of bone and its breakdown products are increasingly used as sensitive markers of bone resorption. The N-terminal peptide-bound crosslinks of type I collagen (NTX) can be measured in urine and is useful for the monitoring of patients with metastatic bone disease. Studies have shown that raised NTX levels in metastatic bone disease correlate with an increased risk of complications and pathological fracture. The development of accurate and instantaneous point of care devices (POCD) would facilitate patient treatment and avoid delays in awaiting results from specialist laboratories. This study assesses the clinical performance of a single use POCD (OSTEOMARK NTx Point of Care Rx Home Use) to monitor NTX levels in patients with metastatic bone disease. NTX was measured in duplicate in 136 urine samples from patients attending clinic with metastatic bone disease using the POCDs. In our centre the frequency of bisphosphonate treatment is dependent on the NTX level, which is categorised into three groups (0-50, 50-100 and >100 nmol BCE/mmol creatinine). We used these categories to compare the clinical performance of the POCDs to that of a laboratory immunoassay. From a total of 272 devices, 231 (84.9%) successfully recorded a value in nM BCE/mM creatinine. Statistical analysis of the measure of agreement between POCD and laboratory assay found moderate agreement between the two assays (kappa 0.508). Out of the 72 samples with a laboratory assay value of <50, 53 (73.6%) were found to be within the same group recorded by POCD. From the 20 samples with a laboratory assay value of >100, 19 (95.0%) were found to be within the same category using POCDs. The measurement of urinary NTX by POCD appears to be a viable option for the monitoring of metastatic cancer patients. Whilst POCDs appear to record higher values than laboratory assays, the correlation between devices is good and with further research the NTX categories could be modified to accommodate this variation.
机译:I型胶原蛋白是骨骼的主要成分,其分解产物越来越多地用作骨吸收的敏感标志物。 I型胶原蛋白(NTX)的N端肽结合交联可以在尿液中进行测量,可用于监测转移性骨病患者。研究表明,转移性骨病中NTX水平升高与并发症和病理性骨折的风险增加有关。精确,即时的即时护理设备(POCD)的开发将有助于患者的治疗,并避免延迟等待专家实验室的结果。这项研究评估了单次使用的POCD(OSTEOMARK NTx护理点Rx家用)在转移性骨病患者中监测NTX水平的临床表现。使用POCD在来自患有转移性骨病诊所的患者的136个尿液样本中一式两份测量NTX。在我们中心,双膦酸盐治疗的频率取决于NTX水平,NTX水平分为三类(0-50、50-100和> 100 nmol BCE / mmol肌酐)。我们使用这些类别将POCD的临床表现与实验室免疫测定的临床表现进行比较。在总共272个设备中,有231个(84.9%)成功记录了nM BCE / mM肌酐的值。对POCD和实验室分析之间的一致性程度进行统计分析,发现两次分析之间的一致性中等(kappa 0.508)。在72个实验室测定值小于50的样品中,有53个(73.6%)属于POCD记录的同一组。使用POCD,从20个实验室测定值大于100的样品中发现19个(95.0%)属于同一类别。通过POCD测量尿中NTX似乎是监测转移性癌症患者的可行选择。尽管POCD的记录值要比实验室检测的值高,但设备之间的相关性很好,并且通过进一步的研究,可以修改NTX类别以适应这种变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号